Merck’s Board of Directors recently elected Robert M Davis as the Chairman of the Board, effective 1st December, 2022. He will succeed Kenneth C Frazier, who plans to retire on 30th Novemeber, 2022, a statement from Merck has notified.
According to the statement, Davis became Merck’s President in April 2021 and was named the company’s Chief Executive Officer (CEO) and a member of its board in July 2021. Prior to that, he was Executive Vice President, Global Services, and the company’s Chief Financial Officer (CFO).
Before joining Merck, Davis was corporate Vice President and President, Medical Products Business, Baxter. During his tenure at Baxter, he held several other positions, including President of Baxter’s Renal business, CFO and Treasurer. Before joining Baxter in 2004, he held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company, the statement mentioned.